JP2009520696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520696A5 JP2009520696A5 JP2008546020A JP2008546020A JP2009520696A5 JP 2009520696 A5 JP2009520696 A5 JP 2009520696A5 JP 2008546020 A JP2008546020 A JP 2008546020A JP 2008546020 A JP2008546020 A JP 2008546020A JP 2009520696 A5 JP2009520696 A5 JP 2009520696A5
- Authority
- JP
- Japan
- Prior art keywords
- pro
- arg
- gly
- glu
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 102000008790 VE-cadherin Human genes 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 108010018828 cadherin 5 Proteins 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000054767 gene variant Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| PCT/AT2006/000465 WO2007070899A2 (de) | 2005-12-23 | 2006-11-10 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009520696A JP2009520696A (ja) | 2009-05-28 |
| JP2009520696A5 true JP2009520696A5 (cg-RX-API-DMAC7.html) | 2009-12-24 |
Family
ID=37846035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546020A Pending JP2009520696A (ja) | 2005-12-23 | 2006-11-10 | 出血性ショックおよびその続発症を治療するための製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7897574B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1962887B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009520696A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080108221A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101365477A (cg-RX-API-DMAC7.html) |
| AT (2) | AT502987A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006326890A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2634026A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE502006004619D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2331970T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL192349A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20083191L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008130413A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007070899A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389653A (zh) * | 2006-02-23 | 2009-03-18 | 菲布雷克斯医疗研究及开发有限责任公司 | 肽和肽衍生物以及含有它们的药物组合物 |
| EP2193370A2 (en) * | 2007-09-24 | 2010-06-09 | Fibrex Medical Research & Development GmbH | Methods of screening for compounds having anti-inflammatory activity |
| US20130324469A1 (en) * | 2010-12-09 | 2013-12-05 | The Brigham And Women's Hospital, Inc. | Fibrinogen and kidney damage |
| US20170112941A1 (en) * | 2015-10-13 | 2017-04-27 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
| JP7506364B2 (ja) * | 2019-10-24 | 2024-06-26 | 国立大学法人東海国立大学機構 | 慢性肺疾患／急性呼吸窮迫症候群の治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997844A (en) | 1991-02-08 | 1999-12-07 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2430972C (en) | 2000-12-12 | 2014-08-05 | Fibrex Medical Research & Development Gmbh | Fibrin fragments for treating inflammation |
| US20080311103A1 (en) | 2004-03-08 | 2008-12-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Anti-Inflammatory Peptides and Methods of Use Thereof |
| AT414097B (de) | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
| WO2006000007A1 (de) | 2004-06-25 | 2006-01-05 | Fibrex Medical Research & Development Gesmbh | Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock |
-
2005
- 2005-12-23 AT AT0206705A patent/AT502987A1/de not_active Application Discontinuation
-
2006
- 2006-11-10 KR KR1020087017988A patent/KR20080108221A/ko not_active Ceased
- 2006-11-10 JP JP2008546020A patent/JP2009520696A/ja active Pending
- 2006-11-10 CA CA002634026A patent/CA2634026A1/en not_active Abandoned
- 2006-11-10 ES ES06804388T patent/ES2331970T3/es active Active
- 2006-11-10 AT AT06804388T patent/ATE440282T1/de active
- 2006-11-10 CN CNA2006800486507A patent/CN101365477A/zh active Pending
- 2006-11-10 AU AU2006326890A patent/AU2006326890A1/en not_active Abandoned
- 2006-11-10 EP EP06804388A patent/EP1962887B1/de active Active
- 2006-11-10 WO PCT/AT2006/000465 patent/WO2007070899A2/de not_active Ceased
- 2006-11-10 RU RU2008130413/15A patent/RU2008130413A/ru not_active Application Discontinuation
- 2006-11-10 US US12/158,670 patent/US7897574B2/en not_active Expired - Fee Related
- 2006-11-10 EP EP09010282A patent/EP2110136A3/de not_active Withdrawn
- 2006-11-10 DE DE502006004619T patent/DE502006004619D1/de active Active
-
2008
- 2008-06-19 IL IL192349A patent/IL192349A0/en unknown
- 2008-07-17 NO NO20083191A patent/NO20083191L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Forbes et al. | Liver fibrogenic cells | |
| Dolmatova et al. | Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation | |
| Guan et al. | Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes | |
| Weng et al. | Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation | |
| Chung et al. | Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model | |
| Bonner | Regulation of PDGF and its receptors in fibrotic diseases | |
| Klöting et al. | Insulin-sensitive obesity | |
| Tsukui et al. | Qualitative rather than quantitative changes are hallmarks of fibroblasts in bleomycin-induced pulmonary fibrosis | |
| Kneidinger et al. | Activation of the WNT/β-catenin pathway attenuates experimental emphysema | |
| Bax et al. | Arterial dissections: common features and new perspectives | |
| Panveloski‐Costa et al. | Thyroid hormone reduces inflammatory cytokines improving glycaemia control in alloxan‐induced diabetic wistar rats | |
| Liu et al. | Ticagrelor attenuates myocardial ischaemia–reperfusion injury possibly through downregulating galectin‐3 expression in the infarct area of rats | |
| JP2013503110A5 (cg-RX-API-DMAC7.html) | ||
| JP2008013542A5 (cg-RX-API-DMAC7.html) | ||
| Mathew et al. | Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective | |
| CO6612254A2 (es) | Polopétidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas | |
| JP2009520696A5 (cg-RX-API-DMAC7.html) | ||
| Quesnel et al. | Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury | |
| Asano | Recent advances in animal models of systemic sclerosis | |
| Yang et al. | Membrane translocation of IL-33 receptor in ventilator induced lung injury | |
| Coll-Bonfill et al. | Slug is increased in vascular remodeling and induces a smooth muscle cell proliferative phenotype | |
| Kim et al. | Differences in genetic signaling, and not mechanical properties of the wall, are linked to ascending aortic aneurysms in fibulin-4 knockout mice | |
| Lin et al. | Pygo1 regulates pathological cardiac hypertrophy via a β-catenin-dependent mechanism | |
| JP2012515165A5 (cg-RX-API-DMAC7.html) | ||
| Kroon et al. | Alterations in expression of elastogenic and angiogenic genes by different conditions of mechanical ventilation in newborn rat lung |